Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ligand Pharmaceuticals Inc. (LGND), Inovio Pharmaceuticals Inc (INO), & Tejon Ranch Company (TRC): Should You Also Buy These Stocks?

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Inovio Pharmaceuticals Inc (NASDAQ:INO) are two stocks from the pharma space that have recently seen insiders buying shares in large quantities. Tejon Ranch Company (NYSE:TRC), one of the largest ranching companies, has also seen its shares being purchased by an insider. Let’s explore each of these insider trades in detail.

Tejon Ranch Company (NYSE:TRC)

Inovio Pharmaceuticals Inc (NASDAQ:INO) is a $600 million market cap, vaccine manufacturing company. A couple of days ago, Peter Keiss, CFO of Inovio Pharmaceuticals Inc (NASDAQ:INO) purchased 3,960 shares of the company at an average price of $10.10 per share. With this purchase, Keiss now owns atotal of 21,388 shares of Inovio Pharmaceuticals Inc (NASDAQ:INO). He also owns 4,500 shares of the company indirectly through his spouse. Cliff Asness‘ AQR Capital Management held over 69,000 shares of the company at the end of second quarter of this year, cutting its stake by 75% on the quarter. Israel Englander’s Millennium Management is bullish on Inovio Pharmaceuticals Inc (NASDAQ:INO), it increased its stake by 96% during the second quarter to over 61,000 shares.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) is a $928 million market cap, biopharmaceutical research company. On October 9, Jason Aryeh, a director of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) purchased 11,000 shares of the company for an average price of $42.99 per share. After this purchase, Aryeh now owns a total of 255,716 shares of the company as a partner of JALAA Equities, LP and JLV Investments, LP. He also owns 5,025 shares of the company indirectly through a trust and 60,695 shares under his own name. David M. Knott’s Dorset Management and Mark Lampert’s Biotechnology Value Fund / Bvf Inc are two institutional investors that are bullish on this stock. As of June 30, 2014, Biotechnology Value Fund owns over 1.89 million shares and Dorset Management owns just under 1.25 million shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND).

Tejon Ranch Company (NYSE:TRC) is a $604 million market cap company, which is one of the largest private landowners in California. On October 9, Norman J Metcalfe, a director of Tejon Ranch Company (NYSE:TRC), bought 3,000 shares of the company at an average price of $29.34 per share and now owns a total of 33,594 shares. Martin Whitman’s Third Avenue Management is one of the largest shareholders of the company and as of June 30, 2014, owns over 2.3 million shares, that amount to over 10% of Tejon Ranch Company (NYSE:TRC). Chuck Royce’s Royce & Associates is bullish on Tejon Ranch Company (NYSE:TRC), raising its stake by 20% during the second quarter of 2014 to over 1.39 million shares.

Disclosure: None

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!